Myriad's Flurizan fails in Phase III Alzheimer's trial
This article was originally published in Scrip
Executive Summary
Myriad Genetics' investigational Alzheimer's disease drug Flurizan (tarenflurbil) has failed in a closely watched Phase III trial.